Caldwell Sutter Capital, Inc. Sellas Life Sciences Group, Inc. Transaction History
Caldwell Sutter Capital, Inc.
- $218 Billion
- Q2 2025
A detailed history of Caldwell Sutter Capital, Inc. transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Caldwell Sutter Capital, Inc. holds 100 shares of SLS stock, worth $190. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$190
Previous $108,000
102.78%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SLS
# of Institutions
84Shares Held
22.6MCall Options Held
1.3MPut Options Held
59.3K-
Vanguard Group Inc Valley Forge, PA6.65MShares$12.6 Million0.0% of portfolio
-
Marshall Wace, LLP London, X02.72MShares$5.16 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.2MShares$4.18 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.49MShares$2.83 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.13MShares$2.14 Million0.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $39M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...